Profile data is unavailable for this security.
About the company
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-53.45m
- Incorporated2021
- Employees42.00
- LocationSurrozen Inc171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 475-2820
- Fax+1 (302) 655-5049
- Websitehttps://www.surrozen.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unity Biotechnology Inc | 0.00 | -27.86m | 24.26m | 19.00 | -- | 1.23 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Cognition Therapeutics Inc | 0.00 | -31.08m | 24.46m | 25.00 | -- | 1.06 | -- | -- | -0.9317 | -0.9317 | 0.00 | 0.5736 | 0.00 | -- | -- | 0.00 | -79.36 | -- | -104.49 | -- | -- | -- | -- | -- | -- | -263.29 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Iterum Therapeutics PLC | 0.00 | -28.34m | 24.75m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Promis Neurosciences Inc | 0.00 | -12.20m | 24.76m | 6.00 | -- | -- | -- | -- | -0.6924 | -0.6924 | 0.00 | -0.1201 | 0.00 | -- | -- | 0.00 | -839.15 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | -- | -- | -- | -- | 26.85 | -- | -- | -- |
Nuo Therapeutics Inc | 1.03m | -2.69m | 25.01m | -- | -- | 41.78 | -- | 24.31 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Lisata Therapeutics Inc | 0.00 | -21.07m | 25.13m | 25.00 | -- | 0.657 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.78m | -40.32m | 25.29m | 57.00 | -- | 0.5483 | -- | 9.10 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Lipocine Inc | 4.80m | -8.49m | 25.51m | 17.00 | -- | 1.20 | -- | 5.31 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Surrozen Inc | 0.00 | -53.45m | 26.13m | 42.00 | -- | 4.31 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Marker Therapeutics Inc | 3.73m | -10.31m | 26.14m | 8.00 | -- | 2.69 | -- | 7.01 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Neurosense Therapeutics Ltd | 0.00 | -11.88m | 26.29m | 16.00 | -- | -- | -- | -- | -0.7299 | -0.7299 | 0.00 | -0.4488 | 0.00 | -- | -- | 0.00 | -350.36 | -- | -5,244.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
IGC Pharma Inc | 1.06m | -13.30m | 26.37m | 67.00 | -- | 3.35 | -- | 24.83 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
Aeon Biopharma Inc | 0.00 | -305.52m | 26.44m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Cue Biopharma Inc | 8.30m | -46.96m | 27.48m | 53.00 | -- | 1.27 | -- | 3.31 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 27.67m | 8.00 | -- | 1.41 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
Vyne Therapeutics Inc | 486.00k | -27.86m | 28.02m | 10.00 | -- | 0.3689 | -- | 57.66 | -2.41 | -2.57 | 0.0162 | 5.15 | 0.0087 | -- | -- | 48,600.00 | -49.92 | -108.41 | -59.60 | -138.57 | -- | -- | -5,732.31 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 30 Jun 2024 | 282.58k | 8.82% |
Armistice Capital LLCas of 30 Jun 2024 | 190.00k | 5.93% |
Nantahala Capital Management LLCas of 30 Jun 2024 | 187.21k | 5.84% |
StemPoint Capital LPas of 30 Jun 2024 | 143.51k | 4.48% |
Euclidean Capital LLCas of 30 Jun 2024 | 87.70k | 2.74% |
Stonepine Capital Management LLCas of 30 Jun 2024 | 66.08k | 2.06% |
Heights Capital Management, Inc.as of 30 Jun 2024 | 64.91k | 2.03% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 60.41k | 1.88% |
ArrowMark Colorado Holdings LLCas of 30 Jun 2024 | 55.12k | 1.72% |
Stanford Management Co.as of 30 Jun 2024 | 52.13k | 1.63% |